Our ambition is to contribute to a sustainable access to health products, such as medicines and medical devices, while promoting manufacturing processes with lower environmental impact, by democratizing carbon footprints within the pharmaceutical and chemical industries.
Ecovamed technology is based on innovative algorithms, coupled with databases that have been specifically designed to assess or validate the geographical origin of drug substance manufacturing across the whole supply chain. This unique technology has been enriched to allow the evaluation of the carbon footprint of fine chemicals and specialty chemicals, from data easily available to manufacturers and at a very attractive cost due to the process automation.
Ecovamed is a technology-oriented company, taking part of the best of data analysis and algorithms, while keeping a strong human component when it comes to the analysis and interpretation of the results.
Promote sincere, honest and scientifically-validated information
Create new technologies that will make these services affordable to all stakeholders
Tackle the societal challenges of
sustainability for health and chemical products
Ecovamed offers competitive and easy-to-use services to label the European origin and Environement index of your health products and calculate the carbon footprint of fine and specialty chemicals
You need the carbon footprint of a chemical you manufacture or you buy?
Ecovamed proposes tailor-made carbon footprints complying with the GHG Protocol standard, at a very competitive price.
Ecovamed specializes in the carbon footprints of active ingredients, their intermediates and more generally fine and specialty chemicals. This focus has enabled the development of an innovative solution to significantly reduce the cost of these footprints, to make them accessible to all stakeholders, without lowering the quality of results.
The objective is to reduce the environmental impact of end-users and also to facilitate the scope 3 calculation and reduction, in creating new purchasing criteria based on the carbon footprint of your suppliers.
You wish to promote the European origin of your health product and its environmental impact?
Ecovamed offers a unique third-party verified label for the manufacturing origin of your drug product and medical devices, including an environmental index.
The Ecovamed label takes into account all stages in the manufacture of drug substances, as well as the formulation of the drug product, to calculate a percentage of European origin, representative of the proportion of stages carried out in Europe. This progressive approach avoids side effects and gives an integral view of the origin.
Originally intended for drugs, this label can also be applied to diagnostic tests, cosmetic products and medical devices. In particular, it makes it possible to obtain additional information on top of the preferential origin of products.
You can either create your account to manage regular projects or request a quotation on a tailor-made project in contacting us.Create my account
If you have regular projects, Ecovamed pricing is based on an annual subscription fee and a low cost fee per project, which depends on the complexity of your product. All our customers are highlithing the competitiveness and high quality of our solution, which is 2 to 3 times less expensive than market average.
Each project, either a label of origin or a carbon footprint, is priced based on the complexity of the product.
For instance, the carbon footprint of a fine chemical made in 3-steps only costs 900 € if you provide production data (bill of material, waste flows, a few plant data…).
A quotation is always provided before each project starts, from information you can provide directly on your account.
Carbon footprint evaluation of Ibuprofen, depending on industrial process & country
This study assessed the carbon footprint of all producers of Ibuprofen around the world. And next month we'll publish on AspirinDownload the report
Carbon footprint evaluation of Metformin, depending on production country
This study assessed the carbon footprint of 7 producers of Metformin, in Europe, India and China.Download the report
Carbon footprint study on nitrile gloves, depending on production country
Ecovamed is starting to publish a series of carbon footprint evaluation of Health Products, comparing various production location.Download the report
Ecovamed has been awarded
by BPI France
This award, with a financial contribution thanks to the "Bourse French Tech", will support the development of our technologyLinkedIn news
Ecovamed joins the ChemTech,
the netwok of innovative start'up
The ChemTech is a joint initiative of France Chimie and Bpifrance, to support start-up developing "chemical-oriented" solutionsChemTech website
Carbon footprint evaluation
of Active Pharmaceutical Ingredients
Publication of the first carbon footprint of Ibuprofen, thanks to newmethodology developed by Ecovamed.Download the report
Chimie Paris Innov welcome Ecovamed
in its incubator
This new location is a great opportunity for Ecovamed to keep innovating within the University Paris Sciences et Lettres (PSL) environmentChimie Paris Innov website
Ecovamed attended the
G5 Santé event in October
The 10th "G5 Santé" meeting held in Paris gave the opportunity to all stakeholders to debate on health innovation and sovereignty
Any questions? Contact us!